title: Apolipoprotein E genotype and risk for development of cataract and age-related macular degeneration.
abstract: OBJECTIVE
  To study whether apolipoprotein E (APOE) genotypes are associated with risk for developing cataract and age-related macular degeneration (AMD).
  
  
  METHODS
  A sample of 88 healthy adults (50-75 years) genotyped for polymorphisms of APOE underwent an eye examination which included visual acuity (VA) testing, slit-lamp cataract evaluation, optical coherence tomography (OCT) and fundus photography, the last of which was analysed and graded for macular pathology at the Reading Centre, Moorfields Eye Hospital, London. Two-by-two cross tables were analysed using the Fisher-Boschloo unconditional full multinomial test. Two-sample t-tests were used for comparing means of scale variables.
  
  
  RESULTS
  Thirty-two participants were diagnosed with cataract or had undergone cataract surgery in one or both eyes, and 56 participants demonstrated no signs of cataract. We found that APOE4 carriers were less likely to have cataract than non-APOE4 carriers (p = 0.039). No correlation between APOE genotypes and morphologic changes in the macular region was revealed. However, APOE3 carriers disclosed significantly higher average macular thickness in both eyes than non-APOE3 carriers (p = 0.012), and APOE3 carriers also had significantly better VA than non-APOE3 carriers (p = 0.041).
  
  
  CONCLUSIONS
  We found no association between AMD and APOE polymorphism in a population of 96 individuals aged 50-75 years. A weak negative association between APOE4 and cataract was uncovered in the same population. Apolipoprotein E3 may be a protective factor against the loss of nerve fibres in the macular region.
authors.affiliation: Eye Department, Ullevål University Hospital, Oslo, Norway. utyg@uus.no
authors.forename: Øygunn A
authors.initials: ØA
authors.lastname: Utheim
authors.forename: Jon Ståle
authors.initials: JS
authors.lastname: Ritland
authors.forename: Tor P
authors.initials: TP
authors.lastname: Utheim
authors.forename: Thomas
authors.initials: T
authors.lastname: Espeseth
authors.forename: Stian
authors.initials: S
authors.lastname: Lydersen
authors.forename: Helge
authors.initials: H
authors.lastname: Rootwelt
authors.forename: Svein Ove
authors.initials: SO
authors.lastname: Semb
authors.forename: Tor
authors.initials: T
authors.lastname: Elsås
mesh_terms: D000368:Aged; D000375:Aging; D053329:Apolipoprotein E2 / Q000235:genetics; D053318:Apolipoprotein E3 / Q000235:genetics; D053327:Apolipoprotein E4 / Q000235:genetics; D001057:Apolipoproteins E / Q000235:genetics*; D002386:Cataract / Q000453:epidemiology* / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease / Q000453:epidemiology; D005838:Genotype; D006801:Humans; D008268:Macular Degeneration / Q000453:epidemiology* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012307:Risk Factors
chemical_list: D053329:Apolipoprotein E2; D053318:Apolipoprotein E3; D053327:Apolipoprotein E4; D001057:Apolipoproteins E